建立双胞胎合作伙伴关系,以改善全球儿童放射治疗结果
Naba Ali1, Elias Amare2, Adugna Fekadu2
1Winship Cancer Institute of Emory University, Atlanta, GA.
JCO global oncology
|February 15, 2024
概括
这项研究详细介绍了埃默里大学和埃塞俄比亚的蒂库尔安贝萨专门医院 (TASH) 之间的成功儿科放射治疗双胞胎计划. 这次合作改善了儿科癌症治疗方案,并成为全球卫生伙伴关系的典范.
科学领域:
- 全球健康 全球健康
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 儿科放射治疗在低收入和中等收入国家 (LMICs) 中至关重要,但具有挑战性.
- 低收入国家和高收入国家 (HICs) 之间的合作可以改善瘤的结果.
- 关于儿科放射治疗双胞胎伙伴关系的文献有限.
研究的目的:
- 在埃默里大学和蒂库尔安贝萨特种医院 (TASH) 之间建立一个儿科放射治疗双胞胎计划.
- 通过国际合作,改善LMIC环境中的儿科瘤护理.
主要方法:
- 埃默里大学和TASH学院的教师和居民之间进行了虚拟沟通和需求评估.
- 在一次面对面访问期间,提供了教育课程和基于实例的实践培训.
- 进行了对儿科瘤资源的需求评估和临床途径的起草.
主要成果:
- 最初的沟通和需求评估确定了关键的教育和机构需求.
- 讲座和实习涵盖了威尔姆斯瘤,脑髓母细胞瘤,神经肌肉瘤,霍奇金淋巴瘤和息性放射治疗.
- 合作结果是起草了临床护理途径,标准操作程序,并建立了虚拟同行评审会议.
结论:
- 全球专家合作加强了儿童癌症治疗方案.
- 这种合作伙伴关系的经验为在放射性瘤学中建立类似的LMIC-HIC合作伙伴关系提供了一个模型.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...